Silibinin: An Inhibitor of Mir-181a Gene Expression in Sk-Br-3 Breast Cancer Cell Line

Indian Journal of Pharmaceutical Education and Research

  • Parvaneh Shahinfar1Department of Cell and Molecular Biology, School of Biological Sciences, Kharazmi University, Tehran, IRAN.
  • Nasrin Motamed2School of Biology, College of Science, University of Tehran, Tehran, IRAN.
  • Elnaz Birjandian2School of Biology, College of Science, University of Tehran, Tehran, IRAN.
  • Omid Shabanpour3Faculty of Medicine, Shahrood Islamic Azad University of Medicine, Shahrood, IRAN.

Volume 51 Issue 4 Pages 597-602

DOI: 10.5530/ijper.51.4.89

Abstract

Background: Mir-181a has been considered as an attractive molecular target for breast cancer therapy. The main objective of this work is to assess the inhibitory effects of silibinin, a herbal substance, on proliferation, apoptosis and Mir-181a gene expression in human breast cancer cell line SK-BR-3. Materials and Methods: Human breast cancer cell line SK-BR-3 was treated with various concentration of silibinin. Cell viability was assessed by MTT assay and apoptosis by flow cytometry. Expression of human mir-181a gene was measured with real-time PCR. Results: Silibinin inhibits growth of SK-BR-3 cells in a dose- and time-dependent manner and effectively induces apoptosis of SK-BR-3 cells. In addition, silibinin caused a decrease in Mir-181a level. Conclusion: These findings suggest that cell viability along with Mir-181a gene expression in breast cancer cells could be reduced by silibinin. These results suggest that silibinin inhibits the proliferation of SK-BR-3 cells, and it induces apoptosis by down-regulating Mir-181a expression in breast cancer cells.

Keywords

  • Silibinin
  • Cell Viability
  • Apoptosis
  • Sk-Br-3 Cell Line
  • Mir-181a
IJOPP

Loading…